These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 22837181)

  • 1. A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer.
    Secord AA; Teoh DK; Barry WT; Yu M; Broadwater G; Havrilesky LJ; Lee PS; Berchuck A; Lancaster J; Wenham RM
    Clin Cancer Res; 2012 Oct; 18(19):5489-98. PubMed ID: 22837181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer.
    Leiser AL; Maluf FC; Chi DS; Sabbatini P; Hensley ML; Schwartz L; Venkatraman E; Spriggs D; Aghajanian C
    Int J Gynecol Cancer; 2007; 17(2):379-86. PubMed ID: 17362316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
    Gould N; Sill MW; Mannel RS; Thaker PH; Disilvestro P; Waggoner S; Yamada SD; Armstrong DK; Wenzel L; Huang H; Fracasso PM; Walker JL
    Gynecol Oncol; 2012 Apr; 125(1):54-8. PubMed ID: 22155262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.
    Strickler JH; McCall S; Nixon AB; Brady JC; Pang H; Rushing C; Cohn A; Starodub A; Arrowood C; Haley S; Meadows KL; Morse MA; Uronis HE; Blobe GC; Hsu SD; Zafar SY; Hurwitz HI
    Invest New Drugs; 2014 Apr; 32(2):330-9. PubMed ID: 24173967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma.
    Franceschi E; Stupp R; van den Bent MJ; van Herpen C; Laigle Donadey F; Gorlia T; Hegi M; Lhermitte B; Strauss LC; Allgeier A; Lacombe D; Brandes AA
    Neuro Oncol; 2012 Dec; 14(12):1503-10. PubMed ID: 23090987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer.
    Blagden SP; Hamilton AL; Mileshkin L; Wong S; Michael A; Hall M; Goh JC; Lisyanskaya AS; DeSilvio M; Frangou E; Stronach EA; Gopalakrishna P; Meniawy TM; Gabra H
    Clin Cancer Res; 2019 Mar; 25(5):1472-1478. PubMed ID: 30563934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
    Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
    Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.
    Chon HS; Kang S; Lee JK; Apte SM; Shahzad MM; Williams-Elson I; Wenham RM
    BMC Cancer; 2017 Jun; 17(1):407. PubMed ID: 28595616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer.
    Basu B; Krebs MG; Sundar R; Wilson RH; Spicer J; Jones R; Brada M; Talbot DC; Steele N; Ingles Garces AH; Brugger W; Harrington EA; Evans J; Hall E; Tovey H; de Oliveira FM; Carreira S; Swales K; Ruddle R; Raynaud FI; Purchase B; Dawes JC; Parmar M; Turner AJ; Tunariu N; Banerjee S; de Bono JS; Banerji U
    Ann Oncol; 2018 Sep; 29(9):1918-1925. PubMed ID: 30016392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.
    Huizing MT; van Warmerdam LJ; Rosing H; Schaefers MC; Lai A; Helmerhorst TJ; Veenhof CH; Birkhofer MJ; Rodenhuis S; Beijnen JH; ten Bokkel Huinink WW
    J Clin Oncol; 1997 May; 15(5):1953-64. PubMed ID: 9164207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
    van der Burg ME; Onstenk W; Boere IA; Look M; Ottevanger PB; de Gooyer D; Kerkhofs LG; Valster FA; Ruit JB; van Reisen AG; Goey SH; van der Torren AM; ten Bokkel Huinink D; Kok TC; Verweij J; van Doorn HC
    Eur J Cancer; 2014 Oct; 50(15):2592-601. PubMed ID: 25096168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma.
    Kimball KJ; Numnum TM; Kirby TO; Zamboni WC; Estes JM; Barnes MN; Matei DE; Koch KM; Alvarez RD
    Gynecol Oncol; 2008 Oct; 111(1):95-101. PubMed ID: 18692224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.
    Haura EB; Tanvetyanon T; Chiappori A; Williams C; Simon G; Antonia S; Gray J; Litschauer S; Tetteh L; Neuger A; Song L; Rawal B; Schell MJ; Bepler G
    J Clin Oncol; 2010 Mar; 28(8):1387-94. PubMed ID: 20142592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer.
    Havrilesky LJ; Alvarez AA; Sayer RA; Lancaster JM; Soper JT; Berchuck A; Clarke-Pearson DL; Rodriguez GC; Carney ME
    Gynecol Oncol; 2003 Jan; 88(1):51-7. PubMed ID: 12504627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.
    Gordon AN; Asmar L; Messing MJ; Street DG; Pippitt CH; Bailey CL; Savage J; Young JA
    Gynecol Oncol; 2004 Aug; 94(2):533-9. PubMed ID: 15297200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma.
    Rose PG; Smrekar M; Fusco N
    Gynecol Oncol; 2005 Feb; 96(2):296-300. PubMed ID: 15661211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
    Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
    Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
    Abaid LN; Micha JP; Rettenmaier MA; Brown JV; Mendivil AA; Lopez KL; Goldstein BH
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):101-7. PubMed ID: 23660691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of alternating doublets of topotecan/carboplatin and paclitaxel/carboplatin in patients with newly diagnosed, advanced ovarian cancer.
    Gordon AN; Hancock KC; Matthews CM; Messing M; Stringer CA; Doherty MG; Teneriello M
    Gynecol Oncol; 2002 Apr; 85(1):129-35. PubMed ID: 11925132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I-II trial of fixed-dose carboplatin and escalating paclitaxel in advanced ovarian cancer.
    Bolis G; Scarfone G; Zanaboni F; Villa A; Presti M; Melpignano M; Ferraris C; Tateo S; Guarnerio P; Gentile A; Parazzini F
    Eur J Cancer; 1997 Apr; 33(4):592-5. PubMed ID: 9274440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.